With a market cap of a miniscule $10.16 million, you can firmly place biotech Capricor Therapeutics (CAPR) in the nano cap section. Although, according to one analyst, if recent developments are anything to go by, the Beverly Hills, California based company won’t be in the small fry category for much longer.H.C. Wainwright’s Joseph Pantginis reiterated a Buy on Capricor along with a $9.00 price target. The implication for investors? Potential upside of a humungous 737%. (To watch Pantginis’s track record, click here)So, what is driving an analyst to set such an extravagant target for such a tiny player? Well, among other reasons, Capricor is one of the companies fighting back against the coronavirus on multiple fronts, both with a search for a vaccine and a possible treatment.Last Friday, Capricor announced that under the compassionate use pathway, CAP-1002, its novel cell therapy currently in clinical development for the treatment of Duchenne muscular...
In recognition to the swift changes COVID-19 has brought to the industry, International Truck has launched International Cares, a grouping of special offers on new truck financing and digital tools. ...
On Monday, workers at an Amazon warehouse in Staten Island walked off the job for a second time, just one week after holding an initial strike, citing continued coronavirus fears amid 26 cases of the virus at the warehouse....
8x8 CEO Vik Verma joins Yahoo Finance’s Seana Smith to discuss the company's increase in usage amid the COVID-19 pandemic, as Zoom encounters concerns over its security and privacy....
Airlines are feeling the pressure of the coronavirus as many carriers reduce flights to NYC, one of the hotspots for the outbreak. Yahoo Finance’s Emily McCormick joins Seana Smith to discuss....
Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19.With a data readout imminent and following an update from CEO Daniel O'Day, an analyst at Cantor Fitzgerald looked at what could lie ahead for the company with respect to remdesivir as a coronavirus treatment.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.The Gilead Analyst Alethia Young maintained an Outperform rating on Gilead with a $78 price target.The Gilead Thesis Gilead shares are likely to move on upcoming remdesivir data that's expected in mid-April from Chinese studies, despite the lack of significant revenue potential, Young said in a Monday note. (See her track record here.)With the company stating all available supply will be given away, there isn't likely to be any revenue impact to 2020, the analyst said.Gilead said it has about...
A fleet-specific webinar on April 7 will address how to access funds, loan forgiveness details, up-to-the-minute federal guidance, and the status of future funding legislation for fleets affected by the COVID-19 pandemic, ...
